rifamycin-sv has been researched along with Tuberculosis--Multidrug-Resistant* in 2 studies
2 other study(ies) available for rifamycin-sv and Tuberculosis--Multidrug-Resistant
| Article | Year |
|---|---|
Novel C-3-(N-alkyl-aryl)-aminomethyl rifamycin SV derivatives exhibit activity against rifampicin-resistant Mycobacterium tuberculosis RpoB
Antimicrobial resistance is a main concern in tuberculosis treatment and is often associated with the emergence of Mycobacterium tuberculosis strains resistant to rifampicin (RIF), which is one of the cornerstones of tuberculosis chemotherapy. In this study, aminoalkyl-aromatic ring tails were appended to the C3 position of rifamycin core to assess the role of C3 substitutions to the anti-mycobacterial activity of the rifamycin antibiotics. The typical hydrazone unit of RIF was replaced by an amino-alkyl linkage to connect the aromatic ring tails with the rifamycin naphthoquinone core. Eight novel C3-(N-alkyl-aryl)-aminoalkyl analogues of rifamycin SV were synthesised and screened in vitro against wild-type HR37Rv and "hypervirulent" HN-878 strains, and a panel of rifampicin-resistant M. tuberculosis clinical isolates carrying mutations at the 522, 531 and 455 positions of the rpoB gene (RpoB Topics: Antitubercular Agents; Binding Sites; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Rifamycins; Structure-Activity Relationship; Tuberculosis, Multidrug-Resistant | 2021 |
[How to use rifamycin rationally: the key issue to prevent multidrug-resistant tuberculosis].
Topics: Antitubercular Agents; Humans; Rifamycins; Tuberculosis, Multidrug-Resistant | 2014 |